The Tiny Cargo Company
Roanoke, VA
- UEI
- V4VBSJU5L458
- CAGE
- 94DU0
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 621 Fugate Rd NE, Roanoke, VA 24012, USA
- Website
- tinycargo.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $209,574 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| This contract is for proof of concept for development to load monoclonal antibodies within GMP-grade milk and… | ACC Aberdeen Proving Ground | $209,574 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Isola Therapeutics Inc. | Minneapolis, MN | 339112 Surgical and Medical Instrument Manufacturing |
| Synedgen, Inc. | Claremont, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Accure Health Inc. | Cambridge, MA | 334516 Analytical Laboratory Instrument Manufacturing |
About the company
The Tiny Cargo Company, doing business as The Tiny Cargo Co, develops and manufactures oral drug-delivery therapeutics using milk-derived extracellular vesicles (MEVs) as a platform for medical countermeasures and radiotherapeutic treatments, operating exclusively as a prime contractor and recipient on federal research awards. A for-profit small business based in Roanoke, Virginia, the company operates under a Total Small Business set-aside posture across its federal footprint.
The Tiny Cargo Company's core capability is the design, development, and scaling of MEV-based oral delivery platforms for radiation-injury mitigation and cancer adjuvant therapy. The company holds an exclusive worldwide license from Virginia Tech covering industrial MEV purification, drug-loading methods, non-cold-chain storage, tissue targeting, and oral delivery, with confirmed freedom-to-operate. Its lead therapeutic, Xolacta, is an orally administered MEV formulation loaded with an esterified drug compound (ACT11-4OME) designed to promote regenerative healing of gastrointestinal tract and bone marrow following ionizing radiation exposure. The platform extends beyond Xolacta to enable oral systemic delivery of other therapeutics and nutraceuticals via MEVs.
Federal funding has concentrated in biomedical research and medical countermeasures across four agencies. The National Institutes of Health National Cancer Institute has funded two project grants since September 2023 (one for Xolacta as an adjuvant therapy during HER2-positive breast cancer radiation treatment, completing August 2027; one for Milacta, a gastrointestinal radioprotective formulation, completing August 2025). The National Center for Advancing Translational Sciences awarded a $985,974 Cooperative Agreement on July 1, 2026 (CFDA 93.350) for industrial production and scaling of Xolacta through June 30, 2028, with support from the Biomedical Advanced Research and Development Authority BlueKnight program and the U.S. Strategic National Stockpile as an identified customer. The National Science Foundation provided a $432,000 Small Business Technology Transfer Phase I grant (June 2022, completed May 2023) for scalability testing of the MEV isolation technology. The U.S. Army Research, Development and Engineering Command awarded a $209,574 firm fixed-price definitive contract in August 2025 (Total Small Business set-aside) for proof-of-concept development to load monoclonal antibodies within GMP-grade milk and lyophilize for shelf stability testing, completing May 22, 2026. Two awards reach ultimate completion within the next twenty-four months, creating recompete exposure. The company operates at early-stage development with preclinical data demonstrating that orally administered Xolacta increased mouse survival by more than 40 percent following lethal ionizing radiation (14 Gy).
Quick answers
Is The Tiny Cargo Company registered in SAM.gov?
Yes. The Tiny Cargo Company's SAM.gov registration is active through July 9, 2027.
How much has The Tiny Cargo Company received in federal contracts?
Federal contracts obligated $209,574 to The Tiny Cargo Company in fiscal year 2025.
How does The Tiny Cargo Company rank among federal contractors?
The Tiny Cargo Company ranked #83 in PSC AN13 in FY2025.
What is The Tiny Cargo Company's most recent federal award?
The Tiny Cargo Company's most recent federal grant award is Industrial production of milk extracellular vesicles for dual-use as a systemic radiotherapeutic medical countermeasure… (U44TR004958), from National Center for Advancing Translational Sciences (NIH), on July 1, 2026.
On GovTribe
See The Tiny Cargo Company's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors